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Currently there is great interest in detecting associations between complex traits and rare variants. In this report, we describe Variant
Association Tools (VAT) and the VAT pipeline, which implements best practices for rare-variant association studies. Highlights of VAT
include variant-site and call-level quality control (QC), summary statistics, phenotype- and genotype-based sample selection, variant
annotation, selection of variants for association analysis, and a collection of rare-variant association methods for analyzing qualitative
and quantitative traits. The association testing framework for VAT is regression based, which readily allows for flexible construction of
association models with multiple covariates and weighting themes based on allele frequencies or predicted functionality. Additionally,
pathway analyses, conditional analyses, and analyses of gene-gene and gene-environment interactions can be performed. VAT is capable
of rapidly scanning through data by using multi-process computation, adaptive permutation, and simultaneously conducting associa-
tion analysis via multiple methods. Results are available in text or graphic file formats and additionally can be output to relational
databases for further annotation and filtering. An interface to R language also facilitates user implementation of novel association
methods. The VAT’s data QC and association-analysis pipeline can be applied to sequence, imputed, and genotyping array, e.g., ‘‘exome
chip,’’ data, providing a reliable and reproducible computational environment in which to analyze small- to large-scale studies with data
from the latest genotyping and sequencing technologies. Application of the VAT pipeline is demonstrated through analysis of data from
the 1000 Genomes project.Despite substantial research efforts to identify associations
between genetic variations and complex disease, the scope
of association studies was previously limited to testing
the common disease, common variant hypothesis. Although
association analysis of common variants has been highly
successful, most of the identified complex-trait associa-
tions explain only a small fraction of total heritability. A
number of population-based sequencing studies demon-
strate the involvement of rare variants in the genetic
etiology of complex traits.1–4 To date, there has been
great interest in further elucidating the role of rare variants
in complex-trait etiology by performing association anal-
ysis with data from whole-genome sequencing, exome
sequencing, and exome genotyping arrays to test the
common disease, rare variant hypothesis. For rare-variant as-
sociation studies, exome sequencing is currently used
more frequently than whole-genome sequencing because
it is substantially less expensive, and it allows integration
of genomic regions of potentially high functional impor-
tance. However, exome sequencing of thousands of sam-
ples can still be prohibitively expensive. In order to address
this problem, researchers have developed exome genotype
arrays (‘‘exome chips’’) as an affordable alternative.5,6 Addi-
tionally, genome-wide complex-trait association studies
that genotyped arrays consisting mainly of common vari-
ants are imputing rare variants from resources such as
the 1000 Genomes project in order to test for rare-variant
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including Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) consortium sequencing
project,7 the National Heart, Lung and Blood Institute
(NHLBI) Exome Sequencing Project (ESP),8 and the T2D
sequencing project,9 are ongoing. These collaborative
studies have generated exome data on millions of variant
sites for thousands of individuals. Upstream pipelines
for sequence alignment and variant calling are well estab-
lished as a result of years of whole-genome sequencing
efforts.10,11 However, downstream association analysis of
whole-genome and exome sequence data poses new
computational and statistical challenges. There is a neces-
sity for well-designed computational analysis tools that
can facilitate quality control (QC) and association analysis
of sequence data.
This report describes Variant Association Tools (VAT), a
software pipeline for QC and association analysis of
sequence, imputed, and genotype array (e.g., ‘‘exome
chip’’ array) data. VAT provides a simple and efficient
way to handle large data sets consisting of genome, exome,
and region-specific variants. It is optimized with a high-
performance data-management infrastructure that is scal-
able for analyzing thousands of samples. VAT facilitates
the creation of versatile and efficient association-analysis
pipelines for QC, selection and filtering of variant sites,
calculation of genotype and sample summary statistics,
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association-testing framework, and it provides a unified
interface to most commonly used rare-variant association
methods.12–21 Here we describe major features of VAT
along with our best-practices data QC and association-
analysis pipeline by using sequence data from the 1000
Genomes project (version 3.0, modified April 30th, 2012).
The data, in variant-call format (VCF), consist of whole-
genome sequence data for 1,092 subjects from 14 popula-
tions (Table S1 in the Supplemental Data available with
this article online). To demonstrate the VAT pipeline, we
focused on single-nucleotide variant (SNV) sites obtained
from the exome-capture arrays. All samples are used for
initial evaluation of sequence-data properties and QC,
and European and Asian samples are used for population-
specific analyses.
VAT has an integrated data-management system,
powered by variant tools,22 that stores variants, samples,
and annotation information in relational databases. With
a flexible configuration system, projects are built by extrac-
tion of selected information from input files generated by
various variant-calling and/or annotation pipelines; file
formats include VCF, CASAVA, Complete Genomics, and
for genotyping arrays, the PLINK file format.23 It is possible
to merge and manage multiple partially overlapping data
from different sources, even those using different genomic
builds. In addition, a number of project-management
operations, including splitting large projects into smaller
subsets (e.g., by selection of samples or genomic regions),
annotating, and tracking subsets of variants and samples,
are provided. The system allows for efficient selection
and filtering on variant sites, genotype calls, variant anno-
tations, and sample phenotypes on the basis of user-speci-
fied QC criteria.
The VAT QC and association-analysis pipeline is illus-
trated in Figure 1, and an outline of best practices is pro-
vided in Figure 2. Variant-, genotype-, and sample-level
QC can flag or remove variant sites, calls, or samples
according to various QC metrics that are provided with
the sequence data; such metrics include allelic balance,
base quality, depth of coverage, and soft QC filters from
machine learning algorithms.10 In an analysis of 15,206
genes represented in the 1000 Genomes data, 365,042
single-nucleotide variants (SNVs) and 17,226 indels on
exome capture targets passed variant-level quality filters.
Additionally, 7,012 SNVs were flagged for having a nonre-
ference allele with frequency of > 50%, and 46,923 SNVs
were flagged for having an ancestral allele which is not
the reference allele. VAT can also efficiently generate a
number of summary statistics that can be used for QC.
For example, transition-transversion ratios (Ti/Tv) can be
calculated and assessed by empirical rules, e.g., ~2 for
whole-genome variants, ~2.7 for novel exome variants,
and ~3.4 for known exome variants. Although most
sequence data have read-depth information for genotype
calls that are typically used for QC, the 1000 Genomes
VCF files do not provide this annotation. Of the variants
included in the VCF file, 0.34% of the genotype calls areThe Amimputed, and 1,793 (0.5%) of the SNV sites have at least
one imputed genotype call. As part of QC, imputed geno-
types and those variant sites missing more than 10% of
their variant calls were removed. The Ti/Tv ratio is 2.72
for novel and 3.44 for known exome variant sites before
QC and is 2.76 and 3.50 after QC, where novel variants
are those submitted to dbSNP only by 1000 Genomes. By
comparing the Ti/Tv ratios before and after QC procedures,
researchers can establish protocols to properly clean
variant sites. If duplicate samples are available, researchers
can calculate the genotype concordance rate before and
after applying different quality filters to determine the pro-
cedure that maximizes the concordance. However, caution
should be used because stringent thresholds that maximize
Ti/Tv ratios and concordance between duplicate pairs can
remove many true-positive variant sites and/or genotype
calls, and this can adversely impact the power of VAT to
detect associations. Other useful summary statistics that
VAT provides for QC include missing genotype call rates,
homozygous and heterozygous genotype counts, allele
or genotype frequencies, synonymous/nonsynonymous
ratios (S/NS), total and average depth of coverage, and
statistics on genotype properties such as minimum,
maximum, and mean genotype-quality scores.
Calculations of QC summary statistics can be flexible
and creative, allowing for construction of customized
queries for specific needs. Summary statistics can be evalu-
ated at variant or sample levels, so that it is possible to con-
dition on other variant, genotype, or sample attributes. For
example, for the 1000 Genomes data, missing genotype
call rates were calculated per variant site (mean 0.55%,
SD 2.7%, max 9.1%, min 0.09%, and median 0.18%) and
per sample (mean 0.34%, stdev 0.41%, max 3.35%, min
0.09%, and median 0.21%). Ti/Tv and S/NS ratios can be
obtained for all variant sites (Ti/Tv 3.22, S/NS 0.73) or for
variants belonging to a specific individual or individuals
(Ti/Tv: mean 3.31, SD 0.045, max 3.45, min 3.16, and
median 3.31; S/NS mean 1.29, SD 0.015, max 1.35, min
1.24, and median 1.29). Researchers can use information
on sample-level missing data and Ti/Tv ratios to determine
whether the variant calls of particular samples are of low
quality. With the use of more than a dozen built-in anno-
tation databases for exome and whole-genome variants,
additional statistics can be generated to aid in a better un-
derstanding of the data or can be used for QC procedures.
The VAT association-analysis pipeline provides popula-
tion-ancestry analysis and detection of related individuals
for QC purposes. Instead of relying on self-reported
ancestry, analyses should assess genetic ancestry from
available genotype data. VAT incorporates multidimen-
sional scaling (MDS) to perform population-structure
inference, and it allows for redesignation of ancestry or
removal of individuals from analysis. We performed global
ancestry and kinship inference for individuals of European
(N¼ 379) and Asian (N¼ 286) ancestry by using SNVs that
had a minor-allele frequency (MAF) of >5% and that were
not in intermarker linkage disequilibrium (LD) (r2 < 0.5).erican Journal of Human Genetics 94, 770–783, May 1, 2014 771
Figure 1. Variant Association Tools Pipeline for Quality Control and Association Analysis.An MAF cut-off of 5% was selected because of the small
sample size; for larger samples, a lower MAF cut-off, e.g.,
0.1%, should be used. Figure 3 displays results from the
MDS analysis; the first and second components are
plotted. It can be observed that the European and the Asian
populations are clearly separated (Figure 3A). When the
MDS components for only Europeans are plotted, it is
observed that the Finnish (FIN) cluster is separated from
the other European groups, and there is the greatest over-772 The American Journal of Human Genetics 94, 770–783, May 1, 2lap between the Utah residents with Northern and
Western European ancestry (CEU) and the British (GBR)
(Figure 3B). It is also observed for Asians that the two
Chinese populations (CHB and CHS) cluster separately
from the Japanese (JPT) (Figure 3C). These observations
are expected on the basis of the population histories. How-
ever, for both Europeans and Asians we observe subclusters
within each population (Figures 3B and 3C). We suspected
that such a pattern might have been due to batch effects014
Figure 2. Best Practices for Implementing the Variant Association Tools Pipeline.because sequencing of 1000 Genomes data was performed
on three platforms (Illumina, ABI Solid, and LS454). There-
fore, we performed MDS analysis with this information
and found that, indeed, the subclusters could be attributed
to the use of different sequencing platforms (data not
shown).
Within each population group, one can perform kinship
analysis to identify and remove cryptically related and
duplicate samples. VAT incorporates a robust pair-wise
relationship inference algorithm to estimate kinship coef-
ficients and output pairs of samples that are duplicate or
MZ twins or first-degree, second-degree, or third-degree rel-
atives.24 In practice, only one sample from each duplicate
pair or relative group should be retained in association
analysis unless empirical p values for association tests are
obtained or mixed models are used. Subjects to be retainedThe Amin the analysis should be determined by availability of
phenotype data and quality of sequence data. Kinship
inference indicates that, of the 379 DNA samples from Eu-
ropeans, there were four cryptically related individuals,
whereas of the 286 individuals from Asian populations,
one individual is a child of a trio and eight individuals
are cryptically related. It should be noted that performing
kinship inference requires the use of caution because sub-
populations can cause individuals to appear to be closely
related, e.g., third-degree relatives who in reality are either
more distantly related or unrelated. We therefore per-
formed kinship inference separately not only for Asians
and Europeans but also for each subpopulation listed in Ta-
ble S1 and also for each sequencing platform (data not
shown). The 375 unrelated European and 277 unrelated
Asian exomes were used for further analysis.erican Journal of Human Genetics 94, 770–783, May 1, 2014 773
Figure 3. Global Ancestry Inference
Ancestry inference was performed using MDS analysis with graphic presentation of projection of samples to the first two MDS compo-
nents. Color codes represent the region of collection or self-reported ancestry. MDS analysis was performed for all European and Asian
samples (A); European samples (B); and Asian samples (C).Researchers can determine whether the reported sex is
consistent with genetic data by examining the heterozy-
gosity of markers on the X chromosome and presence of
Y chromosomal variants. Inconsistencies are often due to
sample swaps, but they can also occur for unreported cases
of Turner or Klinefelter’s syndrome. In the situation where
it is believed that inconsistencies are due to sample swaps,
the samples in question should be removed because other
phenotypic data might also be inconsistent. In the 1000
Genomes data, no inconsistencies between reported and
genomic sex were detected.
It is advisable to remove those sites that deviate from
Hardy-Weinberg equilibrium (HWE) because the deviation
can be caused by genotyping error.25 VAT provides an
efficient exact test of HWE.26 For case-control data, only
controls should be tested for deviations fromHWE because
for cases, sites associated with disease status can deviate
from HWE. Additionally, because population substructure
can cause deviations from HWE, if more than one popula-
tion is analyzed, each population should be tested sepa-
rately. For the 1000 Genomes data, 345 SNV sites for
Europeans and 340 SNV sites for Asians deviated from
HWE (p value < 5 3 107) and were removed from further
analysis.27
The remaining 170,245 SNV sites (106,920 European
and 96,593 Asian SNV sites) were annotated with the
built-in ANNOVAR pipeline. A number of summary statis-
tics, including variant counts categorized by functional
type and MAF, were computed for the European and Asian
exome data. For European and Asian samples combined,
Figure 4A displays the number and proportion of synony-
mous, missense, and nonsense variant sites, and Figure 4B
displays the number and proportion of variant sites by
MAF for synonymous, missense, and nonsense variants.
It can be observed that the greatest number of variant sites
are missense and that the least number are nonsense (Fig-
ures 4A and 4B). For synonymous, missense, and nonsense774 The American Journal of Human Genetics 94, 770–783, May 1, 2variants, most variant sites have frequencies of <1%, and
the majority are singletons. The greatest proportion of
singletons can be found in nonsense variants (67.5%), fol-
lowed by missense (52.6%) and synonymous (42.2%) var-
iants (Figure 4B). Figure 4C displays the average number of
variant sites per individual for Europeans, Asians, and
both. Asians have on average 18,583 variant sites per indi-
vidual, which is greater than the 17,883 variant sites for
Europeans (two-sample t test, p value ¼ 1.06 3 1067).
The majority of per-individual variant sites are synony-
mous (Asian [56.1%], European [56.1%]), followed by
missense (Asian [43.6%], European [43.6%]) and then
nonsense (Asian [0.3%], European [0.3%]). Figure 4D
shows the average number of singletons per individual.
Although there are more singletons for Asians (N ¼
163 5 33) than Europeans (N ¼ 112 5 35), their propor-
tions by functional type are approximately the same for
the two populations. Additionally, it is possible to investi-
gate at the variant level which sites are unique to a popula-
tion or shared between populations. Table 1 summarizes
the shared and unique exonic variant sites between
Europeans and Asians. For variant sites unique to the two
populations, the proportion of singleton sites is greater
in Asians than in Europeans for all functional types
(p values < 2 3 1016). Proportions of shared variants
are significantly different between functional types
(p values < 2 3 1016). Of the 33,268 exonic SNVs shared
by the two populations, 33.6% of the variant sites show a
significant difference in MAF (p < 1.5 3 106, which is a
p value of 0.05, for which a Bonferroni correction is per-
formed for testing ~33,000 variant sites). The results are
obtained with a Fisher’s exact test provided in VAT, which
can also be used to evaluate simple hypotheses such as
those regarding the difference in MAF between groups of
samples and heterozygote excess and deficiency.
VAT can also perform QC of the phenotypic data. Indi-
viduals to be included or excluded from analysis can be014
Figure 4. Variant- and Sample-Level Summary Statistics for European and Asian Samples by Variant Functional Type: Missense,
Synonymous, and Nonsense
Variant-level statistics are displayed as the number and percentage of variant sites by functional type (A) and the frequency of
variant sites by functional type (B) for Europeans and Asians combined. Sample-level statistics are displayed as average number of
variants per individual by functional type for Europeans, Asians, and the two populations combined (C) and the average number
of singletons per individual by functional type for European and Asians separately (D). (C) Error bars represent standard error of
the mean.selected on the basis of information from multiple pheno-
types, e.g., for the study of hypertension, controls with
evaluated systolic and/or diastolic blood pressure can be
excluded. If covariates are to be included in the analysis,
missing covariate values can be replaced with the mean
covariate value so that individuals with missing values do
not need to be removed from the analysis. Quantitative
phenotypes should be examined for outliers. If outliers
are present, Winsorization should be applied unless the
outliers are deemed unreliable, in which case they should
be removed. For association analysis of quantitative traits,
many tests require trait values to be normally distributed.
Therefore, VAT can perform square root, logarithmic, and
quantile normal (also called rank-based inverse normal)
transformations. VAT can generate graphic summaries of
phenotypic data to allow investigation of the normality
of quantitative traits, outliers, and variability between
samples, e.g., phenotype distributions in different study
groups. In Figure 5A the left panel displays the simulated
body mass index (BMI) phenotypes for Europeans; we
generated phenotype data separately for Europeans and
Asians by first simulating height and weight values
under normal distribution and then calculating BMI with
the equation BMI ¼ Weight/Height2. The center panel dis-
plays the BMI phenotype data after log10 transformation,The Amand the right panel displays the results after quantile
normalization.
Association testing between individual variants and
complex traits is standard practice in genome-wide associ-
ation studies of common variants, and VAT can perform
single-variant association analysis. However, it is well
established that single-variant tests are underpowered to
detect rare-variant associations. Instead, rare-variant asso-
ciation analysis aggregates variants within a region, which
is usually a gene, to perform association tests. A number of
aggregation approaches have been developed to exploit
statistical information from genetic regions where multi-
ple rare variants are harbored.12–21 Such analysis typi-
cally focuses on variants that are most likely to be
functional, e.g., such variants include missense, nonsense,
and splicing sites. Additionally, researchers should apply
an MAF threshold to determine which variants to include
in aggregated analysis. Aggregation of noncausal, higher-
frequency variants can greatly increase type II error. Also,
it is often of interest to detect association signals solely
from rare variants rather than from a mixture of rare and
common variants. The definition of ‘‘rare’’ is arbitrary,
although an MAF of <0.5% or <1% is commonly used.
These cut-offs are typically applied to rare-variant associa-
tion methods by use of a fixed MAF threshold. However,erican Journal of Human Genetics 94, 770–783, May 1, 2014 775
Table 1. Shared and Population-Specific Variant Sites for Europeans and Asians
European Specific Asian Specific
Europeans and
Asians Shared
Proportion of
Shared VariantsSingletons Non-singletons Singletons Non-singletons
All exonic variants 33,725 39,927 38,688 24,637 33,268 0.19
Synonymous 11,704 17,255 13,882 10,380 17,947 0.25
Missense 21,416 22,311 24,203 14,034 15,121 0.15
Nonsense 546 302 540 200 143 0.08for association methods that (1) compute optimized statis-
tics over subsets of variants,15,18 (2) weight variants by
frequency, where higher-frequency variants are down-
weighted,13 or (3) are robust to noncausal variants,28 a
higher MAF cut-off, e.g., 5%, can be used if desired.
During rare-variant association tests there must be at
least two variants present within the tested region. How-
ever, it is often desirable to use more stringent criteria,
e.g., a minimum of three variants, and/or to require that
regions have a minimum cumulative MAF, e.g., 0.5%.
Using these criteria ensures that regions where there is
insufficient power to detect an association are not tested
and thus reduces the number of tests that need to be per-
formed. Usually, for exome analysis a family-wise type I er-
ror of 0.05 implies a significance level of 2.5 3 106 per
test, after Bonferroni correction, for an analysis of 20,000
genes. The per-test significance level can be less stringent
if fewer tests are performed.
It has been demonstrated that the relative power of rare-
variant association tests depends greatly on the allelic
architecture. Of the many rare-variant association tests
that have been developed, no one method is uniformly
the most powerful, and methods tend to be more powerful
if their assumptions closely match those of the underlying
genetic etiology.29–31 Implementation of some rare-variant
methods are available as R packages,14,16 standalone pro-
grams,32 or commercial software, e.g., Golden Helix, but
these implementations focus on a small collection of
methods and lack a complete analysis pipeline or can
only handle a very limited number of samples, both of
which limit their usage. Additionally, as a result of the
large size of association data consisting of thousands of
samples and the fact that many methods depend on
permutation to estimate valid p values, scalability and
efficiency are crucial to high-quality computational tools
for rare-variant association analysis. VAT offers a com-
prehensive collection of rare-variant analysis methods, in-
cluding combined multivariate and collapsing (CMC),12
weighted-sum statistic (WSS),13 kernel-based adaptive clus-
ter (KBAC),14 variable threshold (VT),15 RareCover,18 gene-
or region-based analysis of variants of intermediate and
low frequency (GRANVIL),19 burden of rare variants
(BRV),21 adaptive sum test (AST),20 C-alpha,17 replica-
tion-based test (RBT),33 sequence kernel association test
(SKAT),16 and estimated regression coefficients (EREC).32
In addition to implementing published association776 The American Journal of Human Genetics 94, 770–783, May 1, 2methods, we have made a number of optimizations and
extensions to improve the power and computational effi-
ciency of existing methods. For example, to reduce anal-
ysis time, we developed a ‘‘p value aware’’ VT procedure,
which calculates analytical p values pi for each MAF that
is evaluated. The minimum of pi, pm ¼ min({pi}) gives an
estimate of the smallest possible p value that can be ob-
tained. If pm is larger than a given threshold, e.g., pm >
0.05, a permutation-based p value will not be obtained
because the test is nonsignificant. For the AST method,
instead of fitting the computationally intensive multivar-
iate logistic regression, VAT uses a Fisher’s exact test on
each variant site to determine potentially protective vari-
ants. More details on implementation and modifications
of rare-variant association methods can be found in the
VAT online documentation. Caution is advised during
the application of different association tests because a mul-
tiple-testing penalty reduces rather than increases power.
Although a Bonferroni correction could be applied, it is
overly conservative because the results from rare associa-
tion tests can be correlated. To correct for performing
multiple rare-variant association tests, VAT provides a re-
sampling-based p value adjustment for this particular
multiple-testing problem (see Appendix A).
It has been demonstrated that the type I error for rare-
variant association methods can be increased if there are
differential missing rates between case and control geno-
type data.21 This same increase in type I error can occur
for quantitative traits if there is moremissing data for those
individuals with either high or low quantitative-trait
values. To control type I error, VAT replaces missing geno-
types by a dosage that is based on the observed allele fre-
quencies for that variant site.
All rare-variant association methods, with the exception
of C-alpha, are incorporated in a regression framework,
allowing covariates to be included in the analysis so that
confounding is controlled for and increased type I and II
errors are avoided. Covariates that might be potential con-
founders include age, sex, and population ancestry infor-
mation provided as MDS components. Researchers can
apply model selection procedures to determine which
covariates should be included in the association analysis
model, e.g., researchers can apply step-wise model selec-
tion algorithms by using the Akaike information criterion
(AIC) or Bayes information criterion (BIC).34 Additionally,
the genomic control l can be used for evaluation of the014
number of MDS components to be included in association
analysis.35,36
For analysis of different populations, e.g., Asians and
Europeans, it is not appropriate to analyze all samples
together even if MDS components are used to control for
population substructure. Instead, each population should
be analyzed separately, and the results should be combined
via meta-analysis. Popular meta-analysis methods include
the sample-size-based method or the inverse variance
method,37 Meta-SKAT,38 and Rare METAL.39
In the analysis of 1000 Genomes data, association tests
were performed for the quantile-normalized BMI values
for European and Asian samples separately. It should be
noted that the BMI phenotype data were generated under
the null hypothesis without associations to specific genes.
We controlled for population substructure by including
two MDS components, estimated separately in Europeans
and Asians, in the linear regression model. Sex was also
included as a covariate in the analysis. For the simulated
BMI phenotype, association analyses were performed
with the CMC (Figure 5), BRV (Figure S1), VT (Figure S2),
WSS (Figure S3), and SKAT (Figure S4) methods. Analyses
were performed separately for Europeans and Asians and
then combined via meta-analysis. All p values were
assessed empirically with the exception of SKAT, where
p values were obtained analytically because of the compu-
tational burden of this method. Only missense and
nonsense variants with a MAF of <1% were analyzed,
with the exception of those variants analyzed with the
VT methods, where a cut-off of MAF < 5% was used.
Only those genes with more than three variant sites
(8,933 genes for Europeans, 8,495 genes for Asians) were
analyzed. Although no significant associations with the
simulated phenotype were found, as expected in light of
the fact that the phenotype data were generated under
the null hypothesis, the results can be used for comparing
rare-variant associationmethods. Table 2 displays the com-
parison of the five association methods by the top associa-
tion signals from each method in European data. Of the
28 gene associations listed, none is detected by all of the
five methods. More than half (N ¼ 16) of the genes are
only detected by one method. Detection consistency is
higher among fixed-threshold burden tests (CMC, BRV,
and WSS) than in the variable threshold test (VT) and is
substantially lower between burden tests and variance
component test (SKAT). Analysis of the Asian data pro-
duced similar results (data not shown). In addition to dis-
playing association results as p values, VAT association
analysis provides test-region-specific statistics such as
variants and allele counts, cumulative MAF, number of
samples analyzed per region, missing-data rates, associa-
tion test statistics, effect size values (b values), and standard
errors. VAT performs meta-analysis across different studies
or ethnic groups by combining p values via the sample-size
based and inverse-variance methods37 (Figure 5D; Figures
S1C, S2C, and S3C), as well as the Meta-SKAT method38
(Figure S4C). Results of both meta-analysis and study-The Amspecific analysis are stored andmanaged within the project
database system, making it easy to access specific associa-
tion results, e.g., results with p values below certain
thresholds, and also to readily select and compare results
between association studies. Annotation of association
signals is provided through external databases: A catalog
of published genome-wide association studies40 is used for
annotating association signals that were previously de-
tected in genome-wide association studies; Catalogue of
somatic mutations in cancer (COSMIC)41 is used for anno-
tating genes that were reported in cancer studies to have
somatic mutations; and the Kyoto encyclopedia of genes
and genomes (KEGG)42 database is used for determining
whether detected association signals are involved in
molecular interaction or reaction network. Users can also
upload other external databases of interest in order to pro-
vide additional annotations.
Because every association method has its strengths and
weaknesses, it is appealing to design a mechanism that
takes advantage of different association strategies and
can incorporate as much information as possible. Moti-
vated by the fact that most burden tests for rare-variant
association analysis differ only in genotype coding
and weighting, we developed the VAT stacking algorithm
as a unified association analysis framework. VAT stacking
is a regression-based algorithm that applies likelihood-
ratio statistical inference to test for associations between
(1) qualitative and/or quantitative traits and (2) geno-
typic numeric coding themes, which can incorporate
aggregation and weighting based on MAF or func-
tional annotation as well as genotype-specific weights.
Commonly used external weights are based on protein-
function prediction tools such as PolyPhen2,43 SIFT,44
GREP,45 and CADD,46 which are available from built-in
annotation databases. The VAT stacking algorithm is
outlined in Appendix A. Association testing via VAT
stacking with 1000 Genomes data was performed under
the same settings as those previously described, and
results are shown for analyses incorporating KBAC
weights and KBAC weights stacked on the VT algorithm
(Figure S5).
Researchers can use VAT to perform pathway analysis by
collapsing selected variants from multiple genes within a
pathway into one unit or by collapsing variants within
each gene into separate groups and performing multivar-
iate analysis. Annotations for pathway analysis from
several databases, including KEGG, are provided.42 One
can also use the regression-based framework to test for
the presence of gene-gene or gene-environment interac-
tions. For interaction analysis, one must specify the null
hypothesis in order to test for interactions or to jointly
test for both main effects and interactions. To determine
whether an association signal is being driven solely by a
gene of interest or is due to linkage disequilibrium between
variants within or outside the gene, one can perform con-
ditional association analysis with respect to other genes or
individual variants.erican Journal of Human Genetics 94, 770–783, May 1, 2014 777
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Association analysis of indels can also be performed with
VAT. Indels are first annotated, and potentially functional
indels are then analyzed via rare-variant association
methods through aggregation of either indels or both indel
and SNVs within a region.
When analyzing whole-genome sequence data, in addi-
tion to analyzing coding regions, one can also analyze var-
iants within predicted functional regions, e.g., enhancer
regions, transcription-factor sites, or DNase-I-hypersensi-
tivity sites, by using rare-variant association methods.
Annotations for indels and noncoding variants are avail-
able from the built-in ANNOVAR47 annotation pipeline,
which uses RefSeq48 and ENCODE data.
Imputation is commonly performed with genome se-
quencing data, e.g., 1000 Genomes. After imputation of
rare variants with readily available software such as
MaCH,49 Beagle,50 or IMPUTE2,51 VAT can also be used
for analysis of imputed variants. A variety of information
measures with values lying in the range 0–1 can help to
determine which imputed variant sites are of good
quality.52 Take, for example, the R2 generated by MaCH.
Generally, only those variant sites with a high R2 value,
e.g., R0.8, are analyzed so that the variant calls are of
high quality. R2 can be relaxed so that a greater number
of variants within a region are included in the analysis,
although caution should be used because poorly imputed
SNVs can increase both type I and II errors. For imputed
data, a dosage that takes into account the probabilities
of each of the possible three genotypes is analyzed.53
Imputed variants can be analyzed individually, but it is
also possible to analyze these dosages by using aggregate
association methods such as BRV, WSS, and VT. Addition-
ally, a variety of weighting schemes in VAT stacking can
be applied during analysis of imputed variants.
Implementation of associationmethods in VAT is highly
optimized for computational efficiency and scalability.
Researchers can apply parallel computation to analyze
exomes or genomes by using either one or many different
rare-variant association methods. Flexible permutation
routines are available for efficient evaluation of empirical
p values. It is possible to permute either the phenotype
or genotype predictors for conditional association analysis.
Additionally, two techniques can boost the efficiency of
the permutation routine: (1) ‘‘adaptive’’ permutation, in
which the use of fewer permutations allows researchers
to obtain p value estimates for nonsignificant results and
(2) ‘‘timeout’’ permutation, which ceases when the speci-
fied time limit per test expires; intermediate p values are
reported with a flag so that analysis can be resumed
after the entire association scan is complete. These permu-Figure 5. Distribution of BMI and Rare-Variant Association Analys
(A) The simulated BMI values for Europeans (left), BMI values after l
(right). Analysis of whole-exome association was performed for the qu
For panels (B) to (D), results are represented by p values at thelog10 s
(right) plots. Analysis of Europeans (B) and Asians (C) andmeta-analy
size-based method.
The Amtation techniques are particularly useful in situations
where access to high-performance computing resources is
limited. With these optimizations in action, applying the
CMC method to perform association analysis for 15,206
genes of 1,092 individuals takes around half an hour to
provide empirical p values via permutation on a computer
with AMD Opteron 6220 (16 threads at 3.0GHz) CPU and
WD Black (7200 RPM) hard drive.
The VAT association pipeline can be further customized
through the implementation of user-provided association
methods written in the R language. Researchers can incor-
porate novel association methods in the VAT pipeline and
thus take advantage of various features such as the ability
to handle various input formats, e.g., VCF files, annotation
of variant sites, parallel processing, timeout permutation,
etc. Using the R interface in VAT, researchers can quickly
convert new association methods into a computational
tool that is readily applicable to real-world data.
In summary, VAT is a user-friendly, all-in-one software
pipeline package for rare-variant association analysis. The
data-management system makes it possible for researchers
to constantly update projects as new information is gener-
ated or imported, preventing generation of numerous in-
termediate text files during analysis. With a collection of
generic and versatile commands that select, update, and
execute various queries on variants, genotypes, and sam-
ples, VAT allows researchers to personalize their analysis
without having to write numerous scripts. Most impor-
tantly, in addition to being a powerful tool for data QC
and exploration, the association testing framework in
VAT is the most comprehensive, flexible, and extensible
suite to date. The VAT pipeline provides a standard proto-
col for association analysis of sequence or genotyping array
data via an elegant computational interface and data man-
agement that aids in reproducibility. The VAT package,
documentation, tutorial, and data resources are publicly
available online (see Web Resources).Appendix A
The VAT Stacking Algorithm
We adapted CMC, WSS, GRANVIL, BRV, VT, KBAC,
and RBT methods to a generalized regression model
gðE½YÞ ¼ XTLbþ ZTg, where XL represents sample geno-
type information and Z represents covariates. Let XL
be the generic coding for one sample across a genetic re-
gion L and Gi be the genotype value of locus i (Gi ˛
{0,1,2} or Gi ˛ {0,1} under a dominant or recessive
mode of inheritance, respectively). Coding for CMCis via the CMC Method
og10 transformation (center), and quantile normal transformation
antile-normal-transformed BMI phenotype via the CMCmethod.
cale and displayed in quantile-quantile (QQ) (left) andManhattan
sis of European and Asian results (D) was performed via the sample-
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Table 2. Detection of Association Signals with Five Rare-Variant-Association Methods for European Data
Association Methods CMC BRV VT WSS SKAT
Association Detection Consistency
CMC 100% 80% 30% 50% 30%
BRV 80% 100% 30% 60% 20%
VT 30% 30% 100% 40% 10%
WSS 50% 60% 40% 100% 0%
SKAT 30% 20% 10% 0% 100%
Top Ten Gene Associations Detected by Each Methoda
STON1-GTF2A1L 1.13 3 104 1.05 3 104 7.14 3 104 9.20 3 105 -
ST8SIA5 7.14 3 104 2.26 3 104 4.76 3 104 2.11 3 104 -
ZFP30 3.08 3 104 3.00 3 104 3.75 3 104 - 2.27 3 103
RASIP1 4.55 3 104 4.55 3 104 - - 1.84 3 103
NEBL 4.20 3 105 3.80 3 105 - 1.11 3 104 -
RBFA 6.25 3 104 3.04 3 104 - 8.33 3 104 -
MTF1 3.75 3 104 6.67 3 104 - 5.00 3 104 -
SLC5A1 6.67 3 104 4.76 3 104 - - -
COL19A1 - - 6.60 3 105 4.55 3 104 -
ALDH4A1 - 5.00 3 104 - 2.69 3 104 -
NXNL1 1.11 3 103 - - - 8.66 3 104
BTBD3 - - 1.65 3 104 8.33 3 104 -
MICALL2 - - - - 1.16 3 103
SDCCAG8 - - - - 1.87 3 103
MGST2 - - - - 1.84 3 103
SLC25A18 - 1.00 3 103 - - -
DNAH10 1.00 3 103 - - - -
NLRP7 - - - - 2.45 3 103
FAM167A - - 8.33 3 104 - -
TMCC2 - - - 5.00 3 104 -
ZNF263 - - 8.63 3 105 - -
PCDHA13 - - 7.14 3 104 - -
NAT10 - - 2.20 3 105 - -
PSRC1 - - - - 1.60 3 103
AARS - - - - 4.27 3 104
C8orf12 - - - 6.67 3 104 -
MTRR - - - - 2.23 3 103
HCN3 - - 3.75 3 104 - -
aTotal ¼ 28 genes.ðXL ¼ Ið1;mÞð
Pm
i¼1GiÞÞ and BRV ðXL ¼
Pm
i¼1GiÞ are straight-
forward. The original form of the VT statistic is imple-
mented as a least-squares estimate maximized over all
minor-allele frequencies zTc ¼
Pm
i¼1
Pn
j¼1Ið0;TcÞðTiÞXijðYj
YÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPm
i¼1
Pn
j¼1½Ið0;TcÞðTiÞXij2
q
, which with equivalent VAT
stacking notation, is used for computation of XLðTcÞ ¼780 The American Journal of Human Genetics 94, 770–783, May 1, 2Pm
i¼1Ið0;TcÞðTiÞGi and maximization of the test statistic
zTc ¼
PN
j¼1XLjðYj  YÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPN
j¼1X
2
Lj
q
over all possible MAFs.
One can adapt weighting for WSS, KBAC, and RBT
to analyze either case-control data or quantitative
traits. Weighting for the WSS involves calculation of
variant-site-specific weights on the basis of allele014
frequencies, and individual genotype scores can be repre-
sented as the weighted sum of multilocus genotype values,
XL ¼
Pm
i¼1Gi=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
niqið1 qiÞ
p
, where the weight is based on
the entire sample or a subset of the sample, e.g., on con-
trols. Similarly, the RBT weights can be directly applied to
the equation XL ¼
Pm
i¼1Giwi where wi ¼ logðPrðk1; k01Þ3
½1 Prðk2  1; k02ÞÞ.33 For the KBAC test, the genotype
can be coded as XL ¼ PrðGLÞ ¼
PL
i¼1PrðGi ¼ jÞ, where
the probability is defined by a hypergeometric kernel
FðKu;Ku þ K0u; ðN  KuÞ þ ðN 0  K0uÞ;N 0Þ. Additionally, vari-
ant functional information from the VAT annotation
pipeline is incorporated in VAT stacking as additional
possible weights on the generic genotype matrix, yielding
G0i ¼ fðvÞGi to replace the original genotype coding.
VAT stacking uses a resampling-basedmethod for p value
adjustment when multiple tests are applied to the same
genetic region. For every tth permutation under the VAT
stacking framework, the score statistic z
ðtÞ
i from each asso-
ciation test involved is compared; the statistic that implies
the strongest evidence of association is kept [z
ðtÞ
m ¼
maxðfzðtÞi gÞ for a one-sided test and zðtÞm ¼ maxðf
zðtÞi
gÞ for
a two-sided test]. From the original data set, zm is also
obtained. The adjusted p value is the number of permuta-
tions when z
ðtÞ
m is greater than zm divided by the total
number of permutations. The additional computational
burden involved in obtaining p values adjusted for multi-
ple testing is negligible because their calculations are per-
formed in parallel with estimation of p values for each
association test.Supplemental Data
Supplemental Data include five figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.
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